Zacks Investment Research upgraded shares of Molecular Templates (NASDAQ:MTEM) from a sell rating to a hold rating in a research note published on Wednesday morning.
According to Zacks, “Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered in Austin, United States. “
Several other research firms also recently weighed in on MTEM. BidaskClub raised Molecular Templates from a buy rating to a strong-buy rating in a research report on Friday, December 22nd. ValuEngine downgraded Molecular Templates from a hold rating to a sell rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $5.20.
Molecular Templates (NASDAQ:MTEM) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter. sell-side analysts expect that Molecular Templates will post -1.32 EPS for the current year.
A hedge fund recently bought a new stake in Molecular Templates stock. OxFORD Asset Management LLP bought a new stake in Molecular Templates Inc (NASDAQ:MTEM) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 20,428 shares of the biotechnology company’s stock, valued at approximately $140,000. OxFORD Asset Management LLP owned approximately 0.08% of Molecular Templates at the end of the most recent reporting period. 14.59% of the stock is owned by institutional investors.
About Molecular Templates
Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.